The ZAP-70 § tyrosine kinase plays a critical role in T cell activation and the immune response and therefore is a logical target for immunomodulatory therapies. Although the crystal structure of the tandem SH2 domains of human ZAP-70 in complex with a peptide derived from the ¶ subunit of the T-cell receptor was reported (1), the structure of the kinase domain has been elusive until now. We have crystallized and determined the three-dimensional structure of the catalytic subunit of ZAP-70 as a complex with staurosporine to 2.3 ú resolution utilizing an active kinase domain containing residues 327-606 identified by systematic N-and C-terminal truncations. The crystal structure shows that this ZAP-70 kinase domain is in an active-like conformation despite the lack of phosphorylation on the tyrosines in the activation loop. The unique features of the ATP-binding site, identified by structural and sequence comparison with other kinases, will be useful in the design of ZAP-70-selective inhibitors.
essential role in signaling through the T cell receptor (TCR) (2, 3) . TCR-mediated activation of T cells is crucial to the immune response. Transplant rejection and diseases, such as allergic and autoimmune disorders, have features of a failure to adequately modulate T cell activation. In humans, ZAP-70 gene mutations have been identified that confer lower ZAP-70 protein expression levels or catalytically inactive ZAP-70 proteins (4) (5) (6) . ZAP-70 deficiency results in the absence of mature CD8 + T cells, the prevention of TCR-mediated activation of CD4 + T cells, and it can lead to severe combined immunodeficiency. Peptides that block the association of ZAP-70 with the ¶ subunit (7, 8) and peptides that antagonize ZAP-70 tyrosine kinase activity (9) block T cell activation in vitro. These studies indicate that ZAP-70 antagonists could be useful immunomodulatory therapeutic agents.
ZAP-70 contains two N-terminal SH2 (src homology domain 2) domains and a Cterminal kinase domain. During T cell activation, the binding of ZAP-70 SH2 domains to the phosphorylated ¶ subunit on the activated TCR complex causes a colocalization with the Lck tyrosine kinase that phosphorylates ZAP-70 on Y493 (10, 11) . Also, Previously, the crystal structure of the ZAP-70 SH2 domains in complex with a TCR ¶ subunit peptide was reported (1). As a step toward a better understanding of the structurefunction relationship of ZAP-70 and to assist in the design of selective active site inhibitors, we have determined the crystal structure of the kinase domain of human ZAP-70 to 2.3 ú resolution.
Experimental Procedures

Cloning of ZAP-70 truncated kinase domains
Human ZAP-70 cDNA fragments (Genebank accession number L05148) were synthesized by PCR and cloned using the NcoI (5') and XhoI (3') sites of pTriEx (Novagen), the BamHI (5') and NotI (3') sites of pFastBacHTb (Invitrogen), the BamHI (5') and EcoRI (3') sites of pVL1393 (Invitrogen), or the BamHI (5') and NotI (3') sites of pEBB (16) . The pFastBacHTb plasmids were designed to express N-terminal His-tagged proteins containing the sequence MSYYHHHHHHDYDIPTTENLYFQGAMGSHM prior to the first ZAP-70 residue.
(Invitrogen) using Opti-MEM medium (Gibco-Life Technologies) as described by the manufacturer. After 24 hours, cells were harvested by trypsinization, resuspended in 1X PBS, and collected by centrifugation at 500 × g for 5 minutes. Subsequently, cells were lysed by the addition of 1 mL of 0.5% NP40, 50 mM Tris, pH 8.0, 150 mM NaCl, 2.5 mM MgCl 2 , 1 mM PMSF, 10 mM NaF, 1 mM NaVO 3 , 10% glycerol and complete EDTA-free protease inhibitor tablet (Roche) for 30 minutes on ice. The lysate was clarified by centrifugation at 14,000 × g for 20 minutes at 4°C, and the protein concentration of the supernatant solution estimated by the Bradford Dye Binding Assay (Pierce).
For kinase activity measurements, lysates (1-2 mg total protein) were immunoprecipitated with an anti-HIS antibody (Novagen) and protein A Sepharose CL-4B beads (Amersham Biosciences). The beads were washed three times with lysis buffer and once with kinase buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2.5 mM MgCl 2 , 20 mM MnCl 2 , 200 µM NaVO 3 , 1 mM DTT and 10 mM β-glycerol phosphate) and recovered each time by centrifugation at 16,000 × g for 1 minute. The beads were resuspended in 20 µL kinase buffer with 100 µM ATP and 23 µM A1 peptide (biotinyl-EQEDEPEGDYEEVLE, American Peptide) (17). The reaction was incubated at 37°C for 30 minutes and stopped by adding EDTA to 30 mM. Reaction tubes were centrifuged, and the supernatants were transferred to a Streptavidin coated plate (Pierce) that had been pre-treated with blocking buffer (1X TBS (tris-buffered saline), 0.5X Western Blocking Buffer (Roche)). The plate was incubated at 37 o C for 1 hour, Crystal Structure of ZAP-70 and then washed five times with 1X TBS and 0.1% Tween-20 to remove unbound material. A conjugated secondary antibody (anti-phosphotyrosine antibody-horseradish peroxidase (4G10, Upstate Biotech)) was added (100 µL of a 1:40,000 dilution) and incubated for 30 minutes at room temperature. Following five washes with 1X TBS and 0.1% Tween-20, TMB substrate (Pierce) was added and the plate was incubated at room temperature while shaking. The reaction was stopped after 10 minutes by adding 100 µL of 2M H 2 SO 4 , and the absorbance at 450 nm was read ( Figure 1A ). Full length ZAP-70 (Panvera/Invitrogen) was used as a positive control in each assay.
To verify ZAP-70 recombinant protein expression for every sample, the immunoprecipitated protein was eluted from the beads using 25 µL 1X NuPage Lithium Dodecyl Sulfate sample buffer with NuPage sample reducing agent (Invitrogen) at 70°C for 10 minutes.
The samples were separated by SDS-PAGE and transferred to a PVDF membrane for immunoblotting using a murine anti-ZAP-70 monoclonal antibody (Transduction baculoviruses by standard procedures. A single plaque-purified recombinant baculovirus was amplified to form a high titer virus stock (typically 1-4 × 10 8 p.f.u./mL) (Abgent). SF+ cells (Protein Sciences Corporation) were expanded in 1 L shaker flasks to a concentration of 4 × 10 6 cells/mL in SF-900II SFM medium (Gibco Life Technologies) supplemented with gentamycin (50 µg/ml) and fungizone (250 ng/mL). High titer baculovirus was used to infect 10 liters of SF+ insect cells at a concentration of 1 × 10 6 cells/mL and a multiplicity of infection of 2 in a bioreactor (WAVE Biotech). The cells were harvested after 72 hours by centrifugation at 800 × g for 10 minutes at 4ºC, washed once by resuspension in PBS, and then centrifuged again at 800 × g for 10 minutes. The pelleted cells were stored at -80° C. Protein expression was confirmed by Western blot analysis of lysates with a monoclonal anti-Zap-70 antibody as described above.
Purification of the kinase domain containing residues 327-606-His 7
Frozen cell pellets expressing recombinant human ZAP-70 residues 327-606 (rhZAP70 327-606 ) were thawed at room temperature following the addition of lysis buffer (50 mM Tris-lysate was centrifuged at 30,000 × g for 30 minutes and the supernatant filtered through a glass fiber pre-filter on top of a 0.8 µm membrane (Millipore). In the absence of enzyme activity a fluorescent signal is generated by the europiumpeptide-allophycocyanin complex. Phosphorylated poly(Glu,Tyr) generated by active enzyme displaces the europium-labeled antiphosphotyrosine antibody thereby abrogating the fluorescent signal.
Staurosporine inhibition of rhZAP-70 327-606 was determined using the assay described above with the following modifications. (Table 1) . There was one molecule in the asymmetric unit.
Structure determination and refinement
The initial phases for the Zap-70 structure were obtained by molecular replacement with the program AmoRe (19) . The coordinates of ephrin receptor A2 (B chain, PDB 1MQB) were used as the search model, excluding the N-and C-termini, flexible loops and side chain atoms beyond C². The molecular replacement solution was first refined as two rigid bodies, N-lobe and C-lobe, to optimize the relative orientations of the two lobes. Cycles of structure refinement and manual model building were carried out in CNX and Quanta2000 (Accelrys), respectively. After the first round of refinement, the sequence of ZAP-70 was built in and the missing loops were added in stepwise fashion with each round of model building and refinement. The final model contains residues 328-606 plus 6 of the 7 histidines in the C-terminal His-tag. Residues 327 and Crystal Structure of ZAP-70 359-361 were omitted from the model due to poorly defined electron density. Electron density for AMP-PCP was not observed in the final maps. The refinement statistics are listed in Table 1 .
The coordinates have been deposited in the Protein Data Bank with code ####.
Results and Discussion
Identification of an active ZAP-70 kinase domain
Our first objective was to identify a version of the kinase domain which possesses kinase activity and is crystallizable for structure determination. In many instances, the novel N-and Ctermini of proteins generated by molecular engineering can be crucial for crystallization [reviewed in (20) ]. The amino acid sequence conservation between ZAP-70 and other protein kinases indicated the approximate location of the kinase domain; however, delineation of a stable fragment of the full-length protein needed to be determined empirically. We prepared multiple plasmids with a series of N-and/or C-terminal truncations of the kinase domain, each with a polyhistidine tag, and tested their kinase activity using a mammalian transient transfection assay were tested for kinase activity ( Figure 1A) . A summary of the kinase activity of all truncations analyzed is shown in Figure 1B . N-terminal truncations between residues C254 and D327 yielded active proteins ( Figure 1B) . In contrast, truncations at D335 or L338, caused inactivation of the ZAP-70 kinase fragment as did site-specific modification of a catalytic aspartate residue to asparagine, D479N ( Figure 1B) . Truncation of the C terminus to residue 606 retained kinase activity, whereas deletion to Y593 or Y598 eliminated its activity ( Figure 1B) . These results were consistent with previous reports of activity from GST fusion protein recombinants of the ZAP-70 kinase domain (21, 22) . Therefore, a recombinant ZAP-70 fragment consisting of residues 327-606 is sufficient to yield an active catalytic domain. We performed crystallization trials on several of these active ZAP-70 kinase domains. rhZAP70 327-606 was the shortest one and yielded the best crystals for solving the structure.
Enzymatic properties and crystallization of rhZAP70 327-606
rhZAP70 327-606 was expressed in insect cells and purified to homogeneity with a representative yield of 1.7 mg/L and greater than 90% purity (Figure 2A insert) . Consistent with previous reports (21), the purified kinase domain was found to be more active (7 fold) than full length protein in a TR-FRET competitive immunoassay (Figure 2A ). rhZAP70 327-606 yielded diffraction-quality crystals in the presence of staurosporine and AMP-PCP (Experimental Procedures). Staurosporine, a microbial alkaloid from Streptomyces, is a non-selective, ATPcompetitive inhibitor of many kinases (23) (24) (25) (26) (27) ). In the TR-FRET assay staurosporine inhibited Crystal Structure of ZAP-70 rhZAP70 327-606 with an IC 50 of 55.8 nM ( Figure 2B ).
The overall fold of rhZAP70 327-606
rhZAP70 327-606 exhibits a bilobal architecture that is well conserved among the catalytic domains of protein kinases (Figure 3) . The smaller N-terminal lobe contains a fivestranded antiparallel ² sheet and a single helix (±C) (Figures 3 and 4) . The larger C-terminal lobe is predominantly helical with short strands of β sheet. The two lobes are connected by an extended linker region. The catalytic site (ATP-binding site) is located at the junction between these two lobes and contains staurosporine. The N-terminal lobe has more thermal disorder than the C-terminal lobe, as indicated by the higher temperature factors for the atoms in the Nterminal lobe. The average temperature factor is 60.0 for the N-terminal lobe (residues 328-415) and 47.0 for the C-terminal lobe (residues 416-606-His 6 ).
Analysis of the crystal structure reveals that rhZAP70 327-606 is in an "active" conformation. In the C-terminal lobe, the activation loop contains two regulatory tyrosines involved in trans-and autophosphorylation (Y492 and Y493). Phosphorylation of tyrosines in the activation loop is known to be a mechanism of kinase activation by causing a conformational change of the loop such that the loop no longer blocks protein substrate accessibility (e.g. insulin receptor tyrosine kinase) (28-32). For ZAP-70, phosphorylation of Y493 is required for activation in vivo (10, 11) . In the ZAP-70 structure, the activation loop adopts an open and active-like conformation, without phosphorylation of Y492 or Y493. Also, there was no Crystal Structure of ZAP-70 detectable phosphorylation on Y493 by semi-quantitative Western blot analysis of rhZAP70 327-606 (data not shown). Since part of the activation loop is interacting with a symmetry-related molecule in the crystal, it is impossible to determine from this structure whether the loop was in an active-like conformation in solution prior to crystal packing or whether crystal packing induced the observed conformation. However, a similar conformation of the non-phosphorylated activation loop is observed in the crystal structure of the Chk1-staurosporine complex (33) .
There is a strong correlation between the phosphorylation of full-length ZAP-70 and its activation (3, 7, 11, 21, 22, (34) (35) (36) . In addition, it has been shown that the binding of the SH2 regions to phosphorylated ITAMs or truncation of the SH2 domains causes increased activity of ZAP-70 (7,21,34-37, Figure 2A) . Presumably the N-terminal portion of the protein containing the two SH2 domains is responsible for phosphorylation-dependent activation. Since rhZAP70 327-606 does not contain the SH2 domains, it is plausible that this kinase domain adopts a constitutively active conformation independent of phosphorylation.
The active site of rhZAP70 327-606
At the active site, the side chains of two highly conserved catalytic residues, D461 and N466, in the catalytic loop lie within hydrogen bonding distance of one another (Figures 3 and   4 ). N466 also interacts via a water molecule with D479 in the conserved Asp-Phe-Gly (DFG) motif at the base of the activation loop. A precise spatial arrangement of all three residues is required for optimal phosphotransfer in kinases. In the N-terminal lobe, a salt bridge is formed Crystal Structure of ZAP-70 between two conserved residues, K369 from ²3 and E386 from the ±C helix (Figure 3 ). This salt bridge is also a characteristic feature in active kinase structures (38) .
The glycine-rich or P loop is known to be important for nucleotide and substrate binding, catalysis, and regulation of kinase activity. It has a consensus sequence of GXGX¦G, where X represents any amino acid, and ¦ is usually phenylalanine or tyrosine. This loop forms the upper side of the ATP-binding cleft (Figure 3 ). In the case of ZAP-70, ¦ is F349, and the phenylalanine side chain is folded back into the binding cleft towards staurosporine, limiting solvent accessibility to the active site cavity ( Figure 5A ). A similar conformation was observed for F54 in the cAMP-dependent protein kinase alpha-staurosporine structure ( (25); PDB 1STC) and Y20 in the Chk1-staurosporine structure ((33); PDB 1NVR). Glycine residues make the loop very flexible so that it can adopt different conformations to accommodate the binding of different inhibitors (27, 29, 39) . Additionally, the conformations of the P loop in various kinasestaurosporine complexes can vary considerably. In the ZAP-70 structure, the P loop adopted an extended conformation with F349 bent inward. In contrast, in other staurosporine-bound kinases (40-42), the turn of the P loop is bent downward (in the orientation depicted in Figure 3 and Figure 5A ) which limits the solvent accessibility more than that observed in the ZAP-70 structure. It is possible that additional inhibitors may confer distinct induced-fit configurations of the P loop in ZAP-70 that will be different from the ZAP-70-staurosporine structure.
Binding mode of Staurosporine
In the ZAP-70 structure, staurosporine is located in the cleft between the two lobes Crystal Structure of ZAP-70 ( Figure 3 ) and occupies several subregions of the ATP binding site, classified for drug design purposes by analysis of many kinase-inhibitor structures ( Figure 5B, (43,44) One indole ring occupies the gatekeeper pocket in the back (as oriented in Figure 5A ) while the second indole ring is located in the lipophilic plug region, as shown in Figure 5B . The methyl group of the glycosidic ring partially extends into the region for the triphosphate of ATP.
Overall, the indolylcarbazole moiety of staurosporine makes extensive van der Waals contacts with L344, G345, V352, A367, K369, V399, M414, E415 and M416 from the N-terminal lobe Crystal Structure of ZAP-70 and A417, G420, P421, R465, N466, L468, S478 and D479 from the C-terminal lobe ( Figure   5A ). Most of the interacting residues are notable for their high conservation among protein kinases, contributing to the pan-inhibitory properties of staurosporine.
Structural features for ligand selectivity
Many protein kinase inhibitors emerging from pharmaceutical development are ATP competitors. Although the ATP binding site is generally similar among protein kinases, it has been possible to obtain selectivity by exploiting differences in the mode of ligand interaction in the ATP-binding pocket (45, 46) . This may occur by taking advantage of the unique side chain residues and the induced-fit nature of the flexible loops (such as the P-loop, activation loop or the DFG region). Frequently, the side chains that are closest to the inhibitor are the major determinants of selectivity. Specificity-conferring sites have been revealed from the crystal structures of kinases in complexes with inhibitors. For example, the crystal structure of the Abl-STI-571 (also known as Gleevec and Imatinib) complex revealed that STI-571 formed tight interaction with the activation loop that was in a specific inactive conformation (47, 48) .
From the amino acid alignment of rhZAP70 327-606 with other kinases and our structural data, several residues in the ATP-binding pocket were identified that could be useful as selectivity determinants. We found that the residues in the first turn of the αD helix (Figure 3) are unique in ZAP-70 (G 420 PLHK 424, Figure 4 ). The first turn of the αD helix follows the linker region, and P421 is in van der Waals contact with staurosporine ( Figure 5A ). The Crystal Structure of ZAP-70 underlined residues (P421, H423 and K424, see above) are facing the ATP-binding pocket, forming the "surface site" as defined in Figure 5B , and therefore are available for side chain interactions with potential ligands. In a sequence alignment of 390 protein kinases (49), including ZAP-70, the frequencies for P421, H423 and K424 are 5/390, 22/390 and 11/390, respectively. The P421-H423-K424 combination is unique to ZAP-70 and is conserved in murine ZAP-70. For Syk, the kinase most highly related to ZAP-70, this motif is GPLNK (Figure 4) , and it is conserved in Syk for five mammalian species (human, monkey, murine, pig, rat). The P421-H423-K424 motif therefore creates a unique shape and electrostatic surface in the "surface site" of ZAP-70. Inhibitors designed to optimize the interaction with the GPLHK region might provide selectivity towards ZAP-70.
Gatekeeper residues have also been noted for ligand selectivity in protein kinases (44) . In the ZAP-70 structure, the gatekeeper residue is M414 ( Figure 5 ). The presence of the M414 side chain occludes access to part of the gatekeeper pocket for binding interactions with ligands. This residue may be responsible for the substantial selectivity observed between Lck and ZAP-70 for inhibition by the PP2 antagonist, a potent Src family selective protein tyrosine kinase inhibitor (27). The reported IC 50 value for PP2 was 5 nM against Lck, but only 100 µM against ZAP-70.
In Lck, the gatekeeper residue is threonine (T316), and the smaller threonine side chain permits where I = observed intensity and <I> = average intensity for multiple measurements.
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